参考文献/References:
[1]Lee D,Yu EJ,Ham IH,et al.Clinicopathological implication of insulin-like growth factor-II mRNA-binding protein 3 (IMP3) expression in gastric cancer[J].Anticancer Res,2017,37(1):135-142.[2]Zhang X,Wang DW,Liu BK,et al.IMP3 accelerates the progression of prostate cancer through inhibiting PTEN expression in a SMURF1-dependent way[J].J Exp Clin Cancer Res,2020,39(1):190.[3]Burdelski C,Jakani-Karimi N,Jacobsen F,et al.IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: a tissue microarray study on 8, 877 human cancers and normal tissues[J].Oncol Rep,2018,39(1):3-12.[4]Yang FY,Zhou Q,Meng LQ,et al.IMP3 is a biomarker for non-muscle-invasive urothelial carcinoma of the bladder associated with an aggressive phenotype[J].Medicine (Baltimore),2019,98(27):e16009.[5]Song H,Zheng GQ,Guo XZ,et al.IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma[J].Hum Pathol,2018,81:138-147.[6]Agostini-Vulaj D,Whitney-Miller CL,Gonzalez RS,et al.IMP3 immunohistochemical expression remains consistent among all grades of gastrointestinal neuroendocrine tumors[J].Appl Immunohistochem Mol Morphol,2018,26(4):288-293.[7]Tschirdewahn S,Panic A,Püllen L,et al.Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma[J].Int J Cancer,2019,145(2):531-539.[8]Visser NCM,van der Putten LJM,van Egerschot A,et al.Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study[J].Hum Pathol,2019,89:90-98.[9]Ibrahim TR,Ahmed MM,Hegazy AA.Diagnostic utility of immunohistochemical expressions of IMP3 versus DOG1 and p63 in salivary gland tumors[J].Turk Patoloji Derg,2020,36(3):227-236.[10]Ramirez-Moreno E,Lozano-Lozano M,Ravassa FO,et al.Expression of IMP3 in a retrospective cohort of melanomas with selective lymph node biopsy[J].Dermatol Ther,2020,33(6):e14413.[11]Bellezza G,Prosperi E,del Sordo R,et al.IMP3 is strongly expressed in malignant phyllodes tumors of the breast: an immunohistochemical study[J].Int J Surg Pathol,2016,24(1):37-42.[12]蒋美萍,鞠云鹤.胰岛素样生长因子mRNA结合蛋白3在胰腺癌中的表达及意义[J].中国普通外科杂志,2016,25(9):1271-1275.[13]Kong XD,Xu LN,Cao XX.Correlations of expressions of IMP3 and VEGF with stage of osteosarcoma, microvascular density and pulmonary metastasis[J].J BUON,2020,25(5):2438-2443.[14]Zhang M,Zhao SL,Tan C,et al.RNA-binding protein IMP3 is a novel regulator of MEK1/ERK signaling pathway in the progression of colorectal Cancer through the stabilization of MEKK1 mRNA[J].J Exp Clin Cancer Res,2021,40(1):200.[15]Degrauwe N,Suvà ML,Janiszewska M,et al.IMPs: an RNA-binding protein family that provides a link between stem cell maintenance in normal development and cancer[J].Genes Dev,2016,30(22):2459-2474.[16]Lu LH,Wang SN,Zhu Q,et al.The expression of IMP3 in 366 cases with ovarian carcinoma of high grade serous, endometrioid and clear cell subtypes[J].Pathol Res Pract,2018,214(8):1087-1094.[17]Aldera AP,Govender D.Gene of the month: H3F3A and H3F3B[J].J Clin Pathol,2022,75(1):1-4.[18]Okur V,Chen Z,Vossaert L,et al.De novo variants in H3-3A and H3-3B are associated with neurodevelopmental delay, dysmorphic features, and structural brain abnormalities[J].NPJ Genom Med,2021,6(1):104.[19]Amary MF,Berisha F,Mozela R,et al.The H3F3 K36M mutant antibody is a sensitive and specific marker for the diagnosis of chondroblastoma[J].Histopathology,2016,69(1):121-127.[20]宫丽华,张文,董荣芳,等.H3.3 K36M突变蛋白表达在软骨母细胞瘤诊断及鉴别诊断中的价值[J].中华病理学杂志,2021,50(3):242-244.[21]Das L,Shekhar S,Chandrani P,et al.In silico structural analysis of secretory clusterin to assess pathogenicity of mutations identified in the evolutionarily conserved regions[J].J Biomol Struct Dyn,2021:1-10.